Amgen hit as UK suspends Tavneos for new patients
Amgen faces a widening regulatory threat to rare-disease drug Tavneos. The U.K. suspended use for new patients and set a path toward full withdrawal in March 2027, after similar Europe action and proposed U.S. withdrawal.
Amgen NASDAQ:AMGN is facing a broader regulatory challenge for rare-disease drug Tavneos after the U.K. suspended its use for new patients and set a path toward full withdrawal in March 2027. The move follows similar action in Europe and a proposed U.S. withdrawal, increasing the risk that the drug could be removed from multiple markets.